About indivior plc - INDV
Indivior Pharmaceuticals, Inc. is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company is headquartered in North Chesterfield, VA.
INDV At a Glance
Indivior Pharmaceuticals, Inc.
10710 Midlothian Turnpike
North Chesterfield, Virginia 23235
| Phone | 1-804-379-1090 | Revenue | 1.19B | |
| Industry | Pharmaceuticals: Major | Net Income | 2.00M | |
| Sector | Health Technology | 2024 Sales Growth | 8.692% | |
| Fiscal Year-end | 12 / 2025 | Employees | 1,051 | |
| View SEC Filings |
INDV Valuation
| P/E Current | 34.299 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 828.667 |
| Price to Sales Ratio | 1.392 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | 45.92 |
| Enterprise Value to EBITDA | 5.44 |
| Enterprise Value to Sales | 1.438 |
| Total Debt to Enterprise Value | 0.22 |
INDV Efficiency
| Revenue/Employee | 1,130,352.046 |
| Income Per Employee | 1,902.95 |
| Receivables Turnover | 4.125 |
| Total Asset Turnover | 0.725 |
INDV Liquidity
| Current Ratio | 0.894 |
| Quick Ratio | 0.704 |
| Cash Ratio | 0.341 |
INDV Profitability
| Gross Margin | 84.007 |
| Operating Margin | 23.99 |
| Pretax Margin | 1.178 |
| Net Margin | 0.168 |
| Return on Assets | 0.122 |
| Return on Equity | N/A |
| Return on Total Capital | 7.407 |
| Return on Invested Capital | 1.487 |
INDV Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 1,388.889 |
| Total Debt to Total Assets | 28.302 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 1,285.185 |